Current knowledge on pancreatic cancer.
Current knowledge on pancreatic cancer.
复制标题
DOI：
10.3389/fonc.2012.00006
复制
发表时间：
2012
影响因子：
4.7
通讯作者：
Dagorn JC
中科院分区：
文献类型：
--
作者：
Iovanna J;Mallmann MC;Gonçalves A;Turrini O;Dagorn JC
胰腺癌是癌症死亡的第四大原因，中位生存期为6个月，5年生存率为3-5%，令人沮丧。胰腺癌的发生发展是由癌基因的激活、抑癌基因的失活以及多种信号通路的失调引起的。因此，针对这些分子及其下游信号传导的策略可能有助于预防和治疗胰腺癌。然而，尽管胰腺癌的靶向治疗在体外和动物模型中取得了令人鼓舞的结果，但这些发现尚未转化为临床试验的改善结果。这种失败是由于对胰腺癌生物学的不完全理解以及选择效率低下或不完全靶向的药物。在这篇综述中，我们将批判性地介绍目前关于胰腺癌的分子、生化、临床和治疗方面的知识。
Pancreatic cancer is the fourth leading cause of cancer death with a median survival of 6 months and a dismal 5-year survival rate of 3–5%. The development and progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways. Therefore, the strategies targeting these molecules as well as their downstream signaling could be promising for the prevention and treatment of pancreatic cancer. However, although targeted therapies for pancreatic cancer have yielded encouraging results in vitro and in animal models, these findings have not been translated into improved outcomes in clinical trials. This failure is due to an incomplete understanding of the biology of pancreatic cancer and to the selection of poorly efficient or imperfectly targeted agents. In this review, we will critically present the current knowledge regarding the molecular, biochemical, clinical, and therapeutic aspects of pancreatic cancer.